So with that, we’ll address point number 2 and I’ll ask Len to comment in a moment. And just to reiterate, I think clearly, when we launched with 60 sales professionals, I think we accessed around about 8,000 physicians which gives access to around about 35% of the overall marketplace, very focused, very disciplined targeted approach with a strong consensus towards neurologists and high-prescribing primary care physicians. The additional 30 allowed us with much more efficient and smaller territories to be able to drive higher levels of productivity amongst those target physicians as well as to increase that target physician base to around about 11,000 which gives access to around about 40% of the market. And we were delighted, obviously but reps which we put in place at the end of July of last year.
As we got into the fourth quarter of the year, we started to see some significant productivity gains in terms of efficiency, depth of prescribing. And very importantly, the overall growth in relation to prescribers and new prescriptions. And those lead indicators and the productivity benefit of that we’re continuing to see as we moved into the first quarter of this year. So all of our assumptions that went into that increase in size of the sales force, we’re actually seeing manifesting in the marketplace. And Len, I’m sure you want to add some additional color as well.
Leonard Paolillo: Yes. So I think to add on to that, you’ve got the frequency that we’ve been able to increase to our key targets. As Adrian mentioned, we saw growth not only in existing territories but in new territories. And that’s because our reps have smaller geographies and are able to visit these accounts significantly more. And that helps keep the brand top of mind. I mean general awareness is still one of the battles that we fight with the 90-person sales force. And so frequency is a major part of ensuring that clinicians keep Trudhesa top of mind as they’re treating their patients as well as providing a very specific place in therapy. I think you could see our source of business is diverse. However, you can see that patients are getting a lot of value from Trudhesa, both because of the efficacy but also because it could be taken late into an attack.
One of the very unique and important virtues of DHE is that it can reverse central sensitization even when taking late into an attack. So it’s a very valuable tool to healthcare professionals and to patients and really being specific in that messaging, having that pull through in consistent peer-to-peer education meetings which we continue to do at a very good clip in the first quarter, will be important to continue to see the prescription evolution.
Adrian Adams: Thank you, Len and clearly, Stacy, what else bought out here? I mean, you did touch a little bit on incentive aspects, et cetera and I think, obviously, having the right disciplined incentive schemes to drive the appropriate compliance activity with the sales force is very, very important to all of the incentive schemes that we’ve got in place for our quality sales professionals are all with those — driving those lead indicators of new prescribers and new prescriptions very much in the right direction. And we are very pleased with what’s going on at the moment, Stacy.
Operator: Our next question comes from the line of Eddie Hickman with Guggenheim Partners.
Eddie Hickman: Congrats on all the progress. Adrian, can you provide like a bit more color on the assumptions that are going into the guidance that you gave, specifically like in terms of sales force targets and what you would need to see to get to the higher end of that range? And what might need to happen over the year if you were to come in on the lower end of that range? And do you anticipate any inflection at all over the year or a steady cadence? And then I have a follow-up.
